Rufinamide: A new antiepileptic drug treatment for Lennox-Gastaut syndrome

Expert Review of Neurotherapeutics

Volumn 10, Issue 6, 2010, Pages 851-860

  Ferrie, Colin D ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Adult; Adverse effect; Antiepileptic drug; Children; Efficacy; Epilepsy; Lennox Gastaut syndrome; Pharmacodynamics; Pharmacokinetics; Randomized controlled study; Rufinamide

Indexed keywords

BANZEL; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; RUFINAMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ACIDOSIS; ANOREXIA; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; ASTHENIA; ATAXIA; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMMON COLD; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPILEPTIC STATE; FATIGUE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HEAT STROKE; HOLISTIC CARE; HUMAN; HYPERACTIVITY; HYPERSALIVATION; LEARNING DISORDER; LENNOX GASTAUT SYNDROME; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DISEASE; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STEVENS JOHNSON SYNDROME; TONIC SEIZURE; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ANTICONVULSANTS; CHILD; CLINICAL TRIALS AS TOPIC; EPILEPSY, GENERALIZED; HUMANS; SYNDROME; TRIAZOLES;

EID: 77953178314     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.51     Document Type: Review

References (43)

1. Forsgren L, Hesdorffer D. Epidemiology and prognosis of epilepsy. In: The Treatment of Epilepsy (3rd Edition). Shorvon A, Perucca E, Engel J (Eds). Wiley-Blackwell, Oxford, UK 21-31 (2009).
2. Beaumanoir A, Blume W. The Lennox-Gastaut syndrome. In: Epileptic Syndromes in Infancy, Childhood and Adolescence (4th Edition). Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P (Eds). John Libbey Eurotext, Montrouge, France 125-148 (2005).
3. Morita DA, Glauser TA. Lennox-Gastaut syndrome. In: Pediatric Epilepsy: Diagnosis and Therapy (3rd Edition). Pellock JM, Bourgeois BFD, Dodson WE (Eds). Demos, NY, USA 307-334 (2008).
4. Arzimanoglou A, French J, Blume WT et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 8(1), 82-93 (2009).
5. Guerrini R, Parmeggiani L, Bonanni P, Kaminska A, Dulac O. Myoclonic astatic epilepsy. In: Epileptic Syndromes in Infancy, Childhood and Adolescence (4th Edition). Roger J, Bureau M, Dravet C, Genton P, Tassinari CA, Wolf P (Eds). John Libbey Eurotext, Montrouge, France 115-124 (2005).
6. Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive epidemiology of Lennox- Gastaut syndrome among Atlanta children. Epilepsia 38(12), 1283-1288 (1997).
7. Ferrie CD, Patel A. Treatment of Lennox-Gastaut syndrome (LGS). Eur. J. Paed. Neurol. 13(6), 493-504 (2009).
8. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J. Child. Neurol. 20(Suppl. 1), S1-S56 (2005).
9. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord. 9(4), 353-412 (2007).
10. Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst. Rev. 3, CD003277 (2009).
11. McLean MJ, Scmutz M, Pozza M. The influence of rufinamide on sodium currents and action potential firing in rodent neurones. Epilepsia 46(Suppl. 8), 296 (2005).
12. Bialer M, Johannassen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (Eilat IV). Epilepsy Res. 34(1), 1-41 (1999).
13. White HS, Franklin MR, Kupferberg HJ, Schmutz M, Stables JP, Wolf HH. The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia 49(7), 1213-1220 (2008).
14. Schmutz M, Allgeier H, Jeker A et al. Anticonvulsant profile of CGP 33101 in animals. Epilepsia 32(Suppl. 2), 122 (1993).
15. Jain KK. An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Exp. Opin. Invest. Drugs 9(4), 829-840 (2000).
16. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 69(3), 273-294 (2006).
17. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 49(7), 1123-1141 (2008).
18. Critchley D, Fuseau E, Perdomo C, Arroyo S. Pharmacokinetic and pharmacodynamic parameters of adjunctive rufinamide in patients with Lennox-Gastaut syndrome. Epilepsia 46(Suppl. 8), 209 (2005).
19. Waldmeier F, Gschwind HP, Rouan MC, Sioufi A, Czendlik C. Metabolism of the new anticonvulsant trial drug rufinamide (CGP 33101) in healthy male volunteers. Epilepsia 37(Suppl. 5), 167 (1996).
20. Kapeghian JC, Madan A, Parkinson A, Tripp SL, Probst A. Evaluation of rufinamide (CGP 33101), a novel anticonvulsant, for potential drug interactions in vitro. Epilepsia 37(Suppl. 5), 26 (1996).
21. Arroyo S, Sachdeo R, Rosenfeld W, Critchley D, Perdemo C. Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures. Epilepsia 46 (Suppl. 8), 193 (2005).
22. Chang SW, Choi L, Karolchyk MA. A pharmacokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia 39(Suppl. 6), 59 (1998).
23. Biton V. Rufinamide. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, Oxford, UK 647-655 (2009).
24. Fuseau E, Critchley D, Perdomo C, Arroyo S. Population pharmacokinetics drug-drug interaction analysis of rufinamide studies in patients with epilepsy. Epilepsia 46(Suppl. 8), 210-211 (2005).
25. Svendsen KD, Choi L, Chen BL, Karolchyk MA. Single center, open-label, multiple-dose pharmacokinetic trial investigating the effect of rufinamide administration on Ortho-Novum 1/35 in healthy women. Epilepsia 39(Suppl. 6), 59 (1998).
26. Pålhagen S, Canger R, Henriksen O, Van Parys JA, Rivière ME, Karolchyk MA. Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy. Epilepsy Res. 43(2), 115-124 (2001).
27. Elger C, Herman S, Perdomo C, Arroyo S. Dose-range relationships of rufinamide in patients with inadequately controlled partial seizures. Epilepsia 46(Suppl. 8), 83-84 (2005).
28. Todorov A, Biton V, Krauss GL, Perdomo C, Arroyo S. Efficacy and safety of high- versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures. Epilepsia 46(Suppl. 8), 218-219 (2005).
29. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 70(21), 1946-1947 (2008).
30. Biton V, Sachdeo R, Rosenfield W, Schachter S, Perdomo C, Arroyo S. Efficacy and safety of adjunctive rufinamide in patients with inadequately controlled primary generalised tonic-clonic seizures. Epilepsia 46(Suppl. 8), 206 (2005).
31. Kluger G, Glauser T, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Short-term and long-term efficacy and safety of rufinamide as adjunctive therapy in patients with inadequately controlled Lennox-Gastaut syndrome. Epilepsia 47(Suppl. 3), 139 (2006).
32. Kluger G, Kurlemann G, Haberlandt E. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav. 14(3), 491-495 (2009).
33. Krauss GL, Perdomo CA, Arroyo S. Short and long-term safety of rufinamide in patients with epilepsy. Epilepsia 46(Suppl. 8), 213 (2005).
34. Aldenkamp A, Alpherts W. The effect of the new antiepileptic drug rufinamide on cognitive functions. Epilepsia 47, 1153-1159 (2006).
35. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N. Engl. J. Med. 328(1), 29-33 (1993).
36. Motte J, Trevathan E, Aevidsson JFV, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. The Lamictal Lennox-Gastaut Study Group. N. Engl. J. Med. 337(12), 1807-1812 (1997).
37. Fumisuke M, Riaz A. Lamotrigine. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 535-558 (2009).
38. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. The Topiramate YL Study Group. Neurology 52(9), 1882-1887 (1999).
39. Cross JH, Riney CJ. Topiramate. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 673-683 (2009).
40. French J, Tonner F. Levetiracetam. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 559-573 (2009).
41. Wroe JS. Zonisamide. In: The Treatment of Epilepsy (3rd Edition). Shorvon S, Peruca E, Engel J (Eds). Blackwell Publishing, Oxford, UK 713-720 (2009).
42. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 39(Suppl. 3), S2-S10 (1998).
43. Neal EG, Chaffe HM, Edwards N et al. The ketogenic diet in the treatment of epilepsy in children: a randomised, controlled trial (NCT00564915). Lancet Neurol. 7(6), 500-506 (2008).